News

SOCMA said it is unclear if EPA will use the additional time to reconsider establishing a de minimis threshold. SOCMA had earlier, urged EPA to establish a de

Advaxis’ bioengineered Listeria monocytogenes (Lm) carrier system will be used with Collaborator’s influenza multi-antigen technology to produce oral vaccine against influenza. Thomas A. Moore, CEO of Advaxis, said:

Insight enables healthcare institutions to monitor, measure and analyse over 1000 vital financial and clinical performance indicators. Insight is installed in over 100 hospital facilities. Thomas Mann, President

The phase I trial will be conducted on about 30 to 40 patients suffering from solid tumours and had gone through all the treatments available at present. Following

William Shirey, Executive VP of BDI, said: “The fact that our company’s sales for XYNTHA have tracked twenty-two percent (22%) ahead of the results forecasted for the first

Ernest Egli, President of Roche, Latin America, said: “moksha8 has produced strong results for Roche in Brazil and we are delighted to expand our relationship to include Mexico

Jeffrey M. Yordon, CEO of Sagent, said: “Since our inception in 2006, Sagent has successfully executed its strategy by filing more than 70 aNDAs to date, with more

The deal extends reach of Claris’s products in Europe, North America and Australia. Pfizer will undertake the commercialisation of the products that have gone off-patent in the western

The drug is designed to block production of a protein that carries LDL cholesterol in the blood. It met its primary goal in a study of 51 patients